Verubulin hydrochloride: Apoptosis inducer vascular disrupting agent oncolytic

Drugs of the Future

Volumn 35, Issue 12, 2010, Pages 993-997

  Thomas, P ^a   Recht, L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CLOPIDOGREL; COLCHICINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DACARBAZINE; PACLITAXEL; TAXANE DERIVATIVE; TEMOZOLOMIDE; VERUBULIN; VINCA ALKALOID;

AMINATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONSTIPATION; CYCLIZATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; FATIGUE; GLIOBLASTOMA; GLIOMA CELL; HEADACHE; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MICROTUBULE ASSEMBLY; NAUSEA; NEUROPATHY; NONHUMAN; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

EID: 79956203150     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.012.1543302     Document Type: Review

References (27)

1. Sirisoma, N., Pervin, A., Zhang, H. et al. Discovery of N-(4-methoxyphenyl)- N,2- dimethylquinazolin-4-amine, a potent apoptosis induced and efficacious anticancer agent with high blood brain barrier penetration. J Med Chem 2009, 52(8): 2341-51.
2. Jaing, S., Cai, S.X., Pervin, A. et al. (Myrexis, Inc.; EpiCept Corp.). Compounds and therapeutical uses thereof. EP 1660092, JP 2007524637, US 2005137213, US 7618975, WO 2005003100.
3. Cai, S.X., Anderson, M.B., Willardsen, A., Sirisoma, N.S., Zhang, H., Suzuki, K. (Myriad Genetics, Inc.; EpiCept Corp.). Nitrogen containing bicyclic compounds and therapeutic use thereof EP 1833482, WO 2006074147.
4. Anderson, M.B., Willardsen, J.A., Weiner, W.S. et al. (Myrexis, Inc.). Compounds and therapeutical uses thereof. US 2010069383.
5. Foucourt, A., Dubouilh-Benard, C., Chosson, E. et al. Microwave-accelerated Dimroth rearrangement for the synthesis of 4-anilino-6-nitroquinazo- lines. Application to an efficient synthesis of a microtubule destabilizing agent. Tetrahedron 2010, 66(25): 4495.
6. (CBTRUS) CBTRotUS. CBRTUS statistical report. Primary brain and central nervous system tumors diagnosed in the United States in 2004- 2006. Chicago, 2010.
7. Gorlia, T., van den Bent, M., Hegi, M.E. et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981/CE.3. Lancet Oncol 2008, 9(1): 29-38.
8. Walker, M.D., Green, S.B., Byar, D.P. et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303(23): 1323-9.
9. Stupp, R., Mason, W.P., van den Bent, M. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10): 987-96.
10. Muldoon, L.L., Soussain, C., Jahnke, K. et al. Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 2007, 25(16): 2295-305.
11. Smith, Q.R. A review of blood-brain barrier transport techniques. Methods Mol Med 2003, 89: 193-208.
12. Mandula, H., Parepally, J., Feng, R., Smith, Q.R. Role of site-specific binding to plasma albumin in drug availability to brain. J Pharmacol Exp Ther 2006, 317(2): 667-75.
13. Banks, W.A. Physiology and pathology of the blood-brain barrier: Implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 1999, 5(6): 538-55.
14. Fromm, M.F. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000, 38(2): 69-74.
15. Fellner, S., Bauer, B., Miller, D.S. et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002, 110(9): 1309-18.
16. Sioka, C., Kyritsis, A.P. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009, 63(5): 761-7.
17. Savaraj, N., Lu, K., Feun, L.G., Burgess, M.A., Loo, T.L. Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs. Cancer Invest 1987, 5(1): 11-6.
18. Valtonen, S., Timonen, U., Toivanen, P. et al. Interstitial chemotherapy with carmustineloaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 1997, 41(1): 44-9.
19. Westphal, M., Hilt, D.C., Bortey, E. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5(2): 79-88.
20. Ali, M.J., Navalitloha, Y., Vavra, M.W. et al. Isolation of drug delivery from drug effect: Problems of optimizing drug delivery parameters. Neuro Oncol 2006, 8(2): 109-18.
21. Prados, M.D., Schold, S.C., Fine, H.A. et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol 2003, 5(2): 96-103.
22. Uckun, F.M. Rationally designed anti-mitotic agents with pro-apoptotic activity. Curr Pharm Des 2001, 7(16): 1627-39.
23. Kasibhatla, S., Baichwal, V., Cai, S.X. et al. MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 2007, 67(12): 5865-71.
24. Vredenburgh, J.J., Desjardins, A., Herndon, J.E. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30): 4722-9.
25. Grossmann, K.F., Ward, J.H., Akerley, W.L. et al. A clinical study investigating MPC 6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2095.
26. Hwu, W., Akerley, W.L., Stephenson, J. et al. Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8531.
27. Middleton, M.R., Grob, J.J., Aaronson, N. et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18(1): 158-66.